BioSpace News Archive

Seres Therapeutics, Inc. today reported second quarter 2022 financial results and provided business updates.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2022.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Eyam Vaccines and Immunotherapeutics (Eyam), has announced a new licensing agreement for innovative vaccine technologies from the University of British Columbia (UBC), and the James Hutton Institute (JHI).

Quipt Home Medical Corp. today announced that it will host its Fiscal Q3 2022 earnings conference call and audio webcast on Tuesday, August 16, 2022 at 10:00 a.m. (EDT).

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2022 financial and operating results on Tuesday, August 9, 2022 before the market opens.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2022.

Omega Therapeutics, Inc., a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, announced that Thomas McCauley, Chief Scientific Officer, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 8 a.m. ET.

REGENXBIO Inc. (Nasdaq: RGNX) today announced its intention to file a Biologics License Application (BLA) in 2024 using the FDA’s accelerated approval pathway for RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome.

Castle Biosciences, Inc. today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity 42 nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time.